Baker J R, Johnson R N, Scott D J
Br Med J (Clin Res Ed). 1984 May 19;288(6429):1484-6. doi: 10.1136/bmj.288.6429.1484.
The serum fructosamine concentration was examined as a new means to monitor metabolic control in non-insulin-dependent diabetes during changes in management. Weekly fructosamine estimations were compared with glycosylated haemoglobin (HbA1c), 24 hour urinary glucose, and fasting plasma glucose concentrations in a 17 week study entailing withdrawal and reinstitution of oral treatment. The serum fructosamine concentration was more sensitive than the other measurements in detecting a deterioration in diabetic control after stopping oral hypoglycaemic drugs. The response to reinstitution of treatment was not significant in the first three weeks (p = 0.266), despite a highly significant reduction in fasting plasma glucose (p = 0.001) and 24 hour urinary glucose concentrations (p = 0.012). Compared with HbA1c, concentrations of fructosamine appeared more useful in monitoring short term (three to six weeks) changes after alterations in management of diabetes. Additional advantages were lower cost and technical simplicity of measurement.
在非胰岛素依赖型糖尿病患者治疗方案变更期间，血清果糖胺浓度被作为一种监测代谢控制的新方法进行了检测。在一项为期17周、涉及停用和重新启用口服治疗的研究中，每周对果糖胺进行测定，并与糖化血红蛋白（HbA1c）、24小时尿糖及空腹血糖浓度进行比较。在停用口服降糖药后，血清果糖胺浓度在检测糖尿病控制恶化方面比其他测量指标更为敏感。尽管空腹血糖（p = 0.001）和24小时尿糖浓度（p = 0.012）有极显著降低，但在治疗重新启用后的前三周，反应并不显著（p = 0.266）。与HbA1c相比，果糖胺浓度在监测糖尿病治疗方案变更后的短期（三至六周）变化方面似乎更有用。另外的优点是成本较低且测量技术简单。
